Pharmacokinetics

Pharmacokinetics as a Clinical Foundation

Pharmacokinetics (PK) describes what the body does to a drug—the movement of a drug into, through, and out of the body. For the Family Nurse Practitioner, understanding PK is essential for selecting the right dose, route, and frequency to achieve therapeutic effect while minimizing toxicity.^[1] PK is a high-yield topic on board exams (AANP, ANCC) and directly impacts clinical decision-making in primary care, such as adjusting antibiotic doses in renal impairment or choosing transdermal patches for patients with hepatic disease.

Parameters That Define Drug Behavior

• Absorption: Movement of a drug from the site of administration into systemic circulation.^[2] Factors include route, solubility, blood flow, and pH.
• Bioavailability (F): Fraction of an administered dose that reaches systemic circulation unchanged. IV drugs have F=1; oral drugs vary.^[1]
• Distribution: Reversible transfer of drug between compartments (plasma → tissues). Determined by protein binding, blood flow, and tissue affinity.^[2]
• Volume of Distribution (Vd): Theoretical volume needed to contain the total drug amount at the same concentration as plasma. High Vd indicates extensive tissue binding (e.g., digoxin).^[3]
• Metabolism (Biotransformation): Enzymatic conversion of a drug into metabolites (often hepatic). Phase I (oxidation/reduction) and Phase II (conjugation).^[1]
• Elimination: Irreversible removal of drug from the body, primarily renal (urine), but also biliary, pulmonary, or sweat.^[4]
• Half-life (t½): Time for plasma concentration to decrease by 50%. Determines dosing interval.^[2]
• Clearance (CL): Volume of plasma cleared of drug per unit time (mL/min). Total body clearance = renal + hepatic + other.^[3]
• Steady State (Css): Plateau concentration reached after 4–5 half-lives when rate of drug administration equals rate of elimination.^[1]

The ADME Framework and Kinetic Models

The ADME Framework

1. Absorption: For oral drugs, first-pass metabolism (liver) reduces bioavailability. Parenteral routes (IV, IM, SC) bypass first-pass. Transdermal avoids hepatic metabolism.^[2]
2. Distribution: Only unbound (free) drug is pharmacologically active. Albumin binds acidic drugs; α₁-acid glycoprotein binds basic drugs. Renal/hepatic impairment may alter protein binding.^[1]
3. Metabolism: Cytochrome P450 (CYP) enzymes, especially CYP3A4, are responsible for most drug metabolism. Genetic polymorphisms (CYP2D6, CYP2C19) can affect drug response.^[4]
4. Elimination: Glomerular filtration only removes free drug. Creatinine clearance (CrCl) estimates renal clearance. Dose adjustment is required when CrCl < 50 mL/min.^[3]

First-Order vs. Zero-Order Kinetics

• First-order kinetics: Most drugs. A constant fraction of drug is eliminated per unit time (e.g., 50% per half-life). Linear relationship between dose and plasma concentration.^[1]
• Zero-order kinetics: Constant amount eliminated per unit time, regardless of concentration (e.g., ethanol, phenytoin at high doses). Small dose increases can cause large concentration rises → toxicity risk.^[2]

Loading Dose and Maintenance Dose

• Loading dose: One or more doses given initially to achieve therapeutic concentration quickly (e.g., IV amiodarone). Formula: Loading dose = (Vd × desired concentration) / F.^[3]
• Maintenance dose: Dose given to keep concentration at steady state after loading. Formula: MD = (CL × Css) / F.^[1]

Modifiers of Pharmacokinetics in Special Populations

• Age: Neonates have reduced hepatic/renal function; older adults have decreased Vd for water-soluble drugs and reduced clearance.^[4]
• Renal impairment: Prolonged half-life of renally eliminated drugs (e.g., gentamicin, digoxin). Monitor serum levels.^[3]
• Hepatic impairment: Reduced first-pass effect (increased bioavailability), decreased clearance of hepatically metabolized drugs (e.g., warfarin).^[1]
• Pregnancy: Increased Vd, increased renal blood flow, altered enzyme activity (e.g., increased clearance of phenytoin).^[4]
• Drug interactions: Enzyme induction (e.g., rifampin → lower drug levels) or inhibition (e.g., ketoconazole → higher drug levels).^[2]

Using Lab Values to Guide Drug Dosing

• Therapeutic drug monitoring (TDM): Measured for drugs with narrow therapeutic index (e.g., digoxin, lithium, vancomycin, aminoglycosides).^[3]
• Peak and trough levels: Must be drawn at correct times. Trough just before next dose; peak 1 hour after IV (for aminoglycosides) or 2 hours after oral.^[1]
• CrCl estimation: Use Cockcroft-Gault equation to guide dosing adjustments.^[3]
• Liver function tests (LFTs): ALT, AST, bilirubin – assess hepatic metabolic capacity.^[4]

Pharmacokinetics in Therapeutic Decision-Making

• Dose adjustments: In CKD, reduce dose or extend interval. Use a renal dosing guide (e.g., for gabapentin, metformin).^[3]
• Selecting routes: Use non-oral routes if first-pass metabolism is a concern (e.g., sublingual nitroglycerin, transdermal fentanyl).^[2]
• Patient education: Explain timing of doses relative to food (absorption affected by fatty meals). Teach recognition of signs of toxicity.^[1]
• Polypharmacy review: Screen for PK interactions – e.g., antacids reduce absorption of fluoroquinolones; separate by 2 hours.^[4]

Avoiding Toxicity and Adverse Events

• Narrow therapeutic index (NTI) drugs: Digoxin, warfarin, lithium, theophylline. Small changes in concentration can lead to toxicity or loss of efficacy.^[1]
• Drug accumulation: In patients with renal or hepatic impairment, monitor for signs of overdose (e.g., drowsiness with gabapentin, bleeding with warfarin).^[3]
• First-dose phenomenon: For α-blockers (e.g., prazosin) or ACE inhibitors, start with low dose at bedtime to minimize hypotension.^[2]
• Allergic vs. pseudoallergic reactions: Radiocontrast media cause direct mast cell degranulation (not IgE-mediated); premedicate with antihistamines if needed.^[4]

Critical Reminders for Pharmacology Exams

• Memorize the “four processes”: A = Absorption, D = Distribution, M = Metabolism, E = Excretion.
• Know CYP450 inducers vs. inhibitors: Common inducers: rifampin, phenytoin, carbamazepine, St. John’s Wort (RIP-CBS). Common inhibitors: erythromycin, ketoconazole, grapefruit juice, cimetidine (EKG-C).^[2]
• Half-life rule: After one half-life, 50% remains; after two half-lives, 25%; after three, 12.5%; after four, 6.25%; after five, ≈3% (steady state achieved).^[1]
• Volume of distribution interpretation: Low Vd (~5 L) → stays in plasma (e.g., heparin, warfarin). High Vd (>500 L) → extensive tissue binding (e.g., digoxin, SSRI).^[3]
• Bioavailability of common routes: IV = 1, IM/SC = 0.75–1.0, Oral = 0.2–0.8 (variable).^[2]
• “Free drug hypothesis”: Only unbound drug crosses membranes and binds to receptors. In hypoalbuminemia (liver disease, nephrotic syndrome), more free drug is present → higher risk of toxicity despite normal total levels.^[1]
• Classic board questions: Often ask which pharmacokinetic parameter is altered in a given clinical scenario (e.g., cirrhosis → decreased metabolism; CHF → reduced absorption due to gut edema).

References & Sources

1. Woo TM, Robinson MV. Pharmacotherapeutics for Advanced Practice Nurse Practitioners. 5th ed. F.A. Davis; 2022. https://www.amazon.com/Pharmacotherapeutics-Advanced-Practice-Nurse-Prescribers/dp/0803669267
2. Katzung BG, Trevor AJ. Basic & Clinical Pharmacology. 15th ed. McGraw-Hill; 2021. https://accessmedicine.mhmedical.com/content.aspx?bookid=2988§ionid=250593594
3. Bauer LA. Applied Clinical Pharmacokinetics. 4th ed. McGraw-Hill; 2022. https://www.uomustansiriyah.edu.iq/media/lectures/4/4_2019_02_23!03_40_49_PM.pdf
4. Koda-Kimble MA, Young LY. Applied Therapeutics: The Clinical Use of Drugs. 11th ed. Wolters Kluwer; 2018. https://premiumpharmacy.lwwhealthlibrary.com/book.aspx?bookid=2324